Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.

NCT00143208

Last updated date
Study Location
Pfizer Investigational Site
Arezzo, , 52100, Italy
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Glaucoma, Ocular Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of glaucoma (primary open angle, pigmentary, exfoliative) or ocular hypertension (IOP >= 21 mmHG).

- Visual acuity >= 20/200.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Closed/barely open anterior chamber angle or history of acute angle closure glaucoma.


- Hystory of ALT within 3 months prior to the baseline visit.


- History of any ocular filtering surgical intervention.


- Ocular surgery or inflammation/infection within 3 months prior to the baseline visit.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Glaucoma, Ocular HypertensionStudy to Determine if Taking OTC Non-Steroidal Anti-Inflammatory Affects Eye Pressure in Patients Using Glaucoma Drops
NCT00402493
  1. Willingboro, New Jersey
  2. Philadelphia, Pennsylvania
  3. Philadelphia, Pennsylvania
ALL GENDERS
21 Years+
years
MULTIPLE SITES
Glaucoma, Ocular HypertensionA Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.
NCT00638742
  1. Artesia, California
  2. Atlanta, Georgia
  3. Atlanta, Georgia
  4. North Dartmouth, Massachusetts
  5. Minneapolis, Minnesota
  6. Durham, North Carolina
  7. Koebenhavn OE,
  8. Catania,
  9. Coimbra,
  10. Lisboa,
  11. Mayfair West,
  12. Madrid,
  13. Madrid,
ALL GENDERS
0+
years
MULTIPLE SITES
Glaucoma, Ocular HypertensionComparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-Weeks, Masked Evaluator, Phase IV Multi-Center Study in the US
NCT00847483
  1. Belleflower, California
  2. Inglewood, California
  3. San Diego, California
  4. San Diego, California
  5. San Francisco, California
  6. Gainesville, Florida
  7. Lakeland, Florida
  8. Ormond Beach, Florida
  9. Atlanta, Georgia
  10. Bloomingdale, Illinois
  11. Evansville, Indiana
  12. Louisville, Kentucky
  13. Louisville, Kentucky
  14. Shreveport, Louisiana
  15. Bangor, Maine
  16. Kansas City, Missouri
  17. Kansas City, Missouri
  18. Omaha, Nebraska
  19. Las Vegas, Nevada
  20. Bloomfield, New Jersey
  21. Willingboro, New Jersey
  22. Charlotte, North Carolina
  23. Winston-Salem, North Carolina
  24. Streetsboro, Ohio
  25. Oklahoma City, Oklahoma
  26. Tulsa, Oklahoma
  27. Pittsburgh, Pennsylvania
  28. Charleston, South Carolina
  29. Charleston, South Carolina
  30. Charleston, South Carolina
  31. Maryville, Tennessee
  32. Memphis, Tennessee
  33. Dallas, Texas
  34. El Paso, Texas
  35. Houston, Texas
  36. Layton, Utah
  37. Norfolk, Virginia
  38. Norfolk, Virginia
  39. Virginia Beach, Virginia
  40. Wenatchee, Washington
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom In Patients With Poag Or Oh.
Official Title  ICMJE Evaluation Of Intraocular Pressure Lowering-Effect Of Xalacom (Fixed Combination Of Latanoprost And Timolol) In Patients With Poag Or Oh. A 6-Month, Open, Multi-Center Trial In Italy
Brief Summary This study is designed as an open label evaluation of the efficacy of latanoprost and timolol fixed combination (Xalacom) after 6 month of treatment. Eligible patients may be enrolled at the baseline visit. All current ocular hypotensive therapy must be discontinued at this time. On baseline day, patients eligible for the study will receive Xalacom which is to be instilled in the morning.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Glaucoma
  • Ocular Hypertension
Intervention  ICMJE Drug: Xalacom
Study Arms  ICMJE Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: August 31, 2005)
250
Original Enrollment  ICMJE Same as current
Actual Study Completion Date  ICMJE April 2006
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of glaucoma (primary open angle, pigmentary, exfoliative) or ocular hypertension (IOP >= 21 mmHG).
  • Visual acuity >= 20/200.

Exclusion Criteria:

  • Closed/barely open anterior chamber angle or history of acute angle closure glaucoma.
  • Hystory of ALT within 3 months prior to the baseline visit.
  • History of any ocular filtering surgical intervention.
  • Ocular surgery or inflammation/infection within 3 months prior to the baseline visit.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Italy
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00143208
Other Study ID Numbers  ICMJE XALACO-0076-033
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP